Rezdiffra (Resmetirom) Overdose and Accidental Excess Dose

How Resmetirom Works: THR-β Selectivity Explains Its Overdose Profile

Resmetirom is a liver-directed, orally active agonist of thyroid hormone receptor beta. This receptor subtype predominates in hepatocytes, where it regulates lipid metabolism, mitochondrial fatty acid oxidation, and cholesterol clearance. By activating THR-β without meaningful THR-α stimulation, resmetirom reduces hepatic fat and fibrogenic signaling while largely avoiding the tachycardia, atrial fibrillation, and bone loss characteristic of systemic thyroid hormone excess 1.

The clinical relevance to overdose is direct. Thyrotoxicosis from levothyroxine or liothyronine excess causes life-threatening arrhythmias primarily through THR-α activation in cardiomyocytes. Resmetirom's ~28-fold selectivity for THR-β means that even at supratherapeutic exposures, the cardiac risk profile differs substantially from that of conventional thyroid hormone poisoning 2. Phase 1 dose-escalation studies tested resmetirom at doses well above the approved range without observing clinically significant heart rate increases or QTc prolongation 3.

This does not mean overdose is benign. The liver, as the primary target organ, concentrates resmetirom at high levels. Supratherapeutic hepatic exposure could amplify transaminase elevations, and the drug's long half-life (40 to 60 hours) means any toxicity will be sustained rather than self-limited over hours.

What the FDA Label and Clinical Trials Tell Us About Excess Dosing

The Rezdiffra prescribing information does not describe any cases of acute overdose in humans. In the MAESTRO-NASH trial (N=966 randomized to resmetirom), the most common adverse events at therapeutic doses were diarrhea (27% vs. 16% placebo), nausea (22% vs. 13% placebo), and transient transaminase elevations 1. These GI effects were dose-related and generally emerged in the first 12 weeks of therapy.

Preclinical toxicology data submitted to the FDA included repeat-dose studies in rats and dogs at multiples of the human exposure. Findings at high doses centered on expected pharmacologic exaggeration: increased hepatic mitochondrial activity, reduced serum cholesterol below physiologic floors, and modest thyroid axis suppression via negative feedback on TSH. No novel organ toxicity emerged at exposures several-fold above the clinical range 4.

The FDA label recommends that if a dose is missed, patients should skip it and resume the next scheduled dose. It does not instruct on double-dosing. This guidance indirectly confirms the manufacturer's position that a single extra dose is unlikely to produce serious harm.

Pharmacokinetics That Shape Overdose Duration and Severity

Three pharmacokinetic properties govern how a resmetirom overdose behaves clinically.

Long elimination half-life. At 40 to 60 hours, resmetirom's effects persist for days after a single supratherapeutic dose. Steady-state takes roughly 7 to 10 days at normal dosing, so a large acute ingestion in a treatment-naive patient will produce lower peak concentrations than the same dose in someone already at steady state 3.

High protein binding. Resmetirom is more than 99% bound to plasma proteins. This means hemodialysis, hemoperfusion, and exchange transfusion are unlikely to meaningfully accelerate drug clearance. There are no published data on extracorporeal removal of resmetirom, and the pharmacokinetic profile predicts minimal benefit.

Hepatic metabolism via CYP3A4 and CYP2C8. Resmetirom undergoes extensive first-pass hepatic metabolism 4. Co-ingestion of CYP3A4 inhibitors (clarithromycin, itraconazole, grapefruit juice) could increase exposure from an overdose, while CYP3A4 inducers (rifampin, carbamazepine) might partially mitigate it. Clinicians managing an overdose should review the patient's full medication list for these interactions.

Expected Symptoms After an Accidental Excess Dose

No human overdose case series exists for resmetirom. Based on the drug's pharmacology, clinical trial adverse-event data, and preclinical toxicology, the anticipated symptom profile after excess dosing includes several domains 1 4.

Gastrointestinal effects are the most probable early manifestation. Diarrhea and nausea occurred in a dose-dependent pattern in MAESTRO-NASH, and a supratherapeutic dose would be expected to amplify both. Abdominal cramping and possible vomiting could follow a large acute ingestion.

Hepatic effects require monitoring but may not appear immediately. The prescribing information carries a warning about hepatotoxicity, with ALT elevations above 5 times the upper limit of normal reported in 0.4% of resmetirom-treated patients at approved doses. A supratherapeutic exposure could increase this risk. Transaminase peaks typically lag the ingestion by 1 to 4 weeks at therapeutic dosing, so delayed monitoring is appropriate.

Thyroid axis suppression is pharmacologically predictable. Exogenous THR-β activation suppresses TSH via hypothalamic-pituitary negative feedback. After an excess dose, TSH may fall below the reference range, with secondary reductions in free T4 and free T3. This is distinct from clinical hypothyroidism and generally resolves as the drug clears.

Cardiovascular effects should be minimal given THR-β selectivity, but are not impossible at extreme doses. Heart rate monitoring is still warranted. In phase 1 studies, resmetirom did not produce meaningful QTc prolongation even at supratherapeutic concentrations 3.

Stepwise Clinical Management Protocol

The absence of a specific antidote means management follows general toxicologic principles adapted to resmetirom's pharmacology.

Step 1: Assess and stabilize. Obtain vital signs with continuous cardiac monitoring. For presentations within 1 to 2 hours of a large ingestion, consider activated charcoal (50 g in adults) if the patient is alert and protecting the airway. Resmetirom's oral bioavailability and lipophilicity suggest charcoal could reduce absorption, though no data confirm this specifically for resmetirom 5.

Step 2: Contact Poison Control. The American Association of Poison Control Centers (1-800-222-1222) maintains the most current toxicology guidance. For a novel drug with limited overdose experience, poison center consultation is recommended even for asymptomatic presentations.

Step 3: Baseline and serial laboratory monitoring. Draw a comprehensive metabolic panel including hepatic function (AST, ALT, total bilirubin, alkaline phosphatase, albumin), thyroid function (TSH, free T4, free T3), lipid panel, and coagulation studies. Repeat LFTs at 24 hours, 72 hours, 1 week, and 4 weeks after the ingestion. Check thyroid function at 48 to 72 hours and again at 2 weeks.

Step 4: Symptom-directed treatment. Manage diarrhea with oral rehydration and loperamide if needed. Treat nausea with ondansetron. If transaminases rise above 5 times normal, consult hepatology. For asymptomatic TSH suppression alone, observation is sufficient since endogenous thyroid axis recovery follows drug clearance with a half-life of approximately 2 days.

Step 5: Disposition. Asymptomatic patients with a single extra therapeutic dose (e.g., patient accidentally took two 100 mg tablets) can likely be monitored at home with follow-up lab work. Intentional large ingestions or patients with pre-existing liver disease warrant emergency department observation for a minimum of 6 to 8 hours, with outpatient hepatic monitoring arranged at discharge.

How Resmetirom Overdose Differs from Thyroid Hormone Overdose

Clinicians trained in levothyroxine toxicity should recognize that resmetirom overdose does not follow the same playbook. Levothyroxine overdose management centers on cardiac effects: beta-blockers for tachycardia, cooling for hyperthermia, benzodiazepines for agitation. The American Association of Clinical Endocrinologists' 2024 guidance on thyroid hormone excess emphasizes the THR-α-driven sympathetic surge as the primary danger 6.

Resmetirom bypasses this pathway. The expected toxicity is hepatic and gastrointestinal, not cardiovascular. Empiric beta-blocker use is not indicated unless objective tachycardia develops. Cholestyramine, sometimes used in thyrotoxicosis to reduce enterohepatic recirculation of thyroid hormones, has no established role in resmetirom overdose and could alter absorption of co-administered medications.

The one shared concern is thyroid axis suppression. Both levothyroxine excess and resmetirom excess suppress TSH. The clinical difference is that levothyroxine excess produces tissue-level thyrotoxicosis, while resmetirom-driven TSH suppression reflects receptor-mediated feedback without generalized thyrotoxic symptoms 2.

Special Populations: Higher Risk After Excess Dosing

Patients with pre-existing hepatic impairment face the greatest concern. Rezdiffra is contraindicated in decompensated cirrhosis (Child-Pugh B or C), and the prescribing information warns against use in patients with active liver injury (ALT/AST above 5 times normal at baseline) 4. An overdose in these populations could precipitate acute-on-chronic liver failure.

Older adults metabolize resmetirom more slowly due to age-related declines in hepatic blood flow and CYP3A4 activity. Resmetirom exposure may be higher and more prolonged in patients over age 65, warranting extended monitoring after an accidental excess dose.

Patients taking CYP3A4 inhibitors at the time of overdose represent a pharmacokinetic high-risk group. Strong inhibitors such as ketoconazole or ritonavir could increase resmetirom area under the curve by 50% or more based on the drug's metabolic pathway, though formal drug-drug interaction studies at supratherapeutic doses have not been conducted.

Pregnant patients present a theoretical concern. Thyroid hormone receptor activation during organogenesis could affect fetal development, though resmetirom's liver-directed distribution and THR-β selectivity may limit fetal exposure. No human pregnancy overdose data exist. The Rezdiffra label advises pregnancy testing before initiation and effective contraception during treatment.

Reporting and Documentation

Any suspected overdose should be reported to Madrigal Pharmaceuticals' pharmacovigilance team and to the FDA's MedWatch system (1-800-FDA-1088). Because Rezdiffra received accelerated approval in March 2024 based on surrogate histologic endpoints, the FDA requires ongoing post-marketing safety surveillance under the MAESTRO-OUTCOMES confirmatory trial 1. Overdose reports contribute directly to the accumulating safety database that will determine whether Rezdiffra's approval converts to traditional status.

Document the exact number of tablets ingested, time of ingestion relative to last scheduled dose, concomitant medications (especially CYP3A4/2C8 modulators), baseline liver function, and whether the patient was at steady-state dosing. This information enables meaningful aggregate analysis as the post-marketing overdose experience develops.

Clinicians should also check whether the patient is enrolled in the Rezdiffra REMS program or any active Madrigal-sponsored trial, as additional reporting obligations may apply.